Boston Scientific Corp. (BSX) Stock Price Up 2%
Shares of Boston Scientific Corp. (NYSE:BSX) rose 2% during trading on Thursday . The stock traded as high as $24.31 and last traded at $24.29, with a volume of 5,405,102 shares changing hands. The stock had previously closed at $23.82.
BSX has been the subject of several analyst reports. Leerink Swann reaffirmed a “buy” rating and set a $27.50 price objective (up from $25.50) on shares of Boston Scientific Corp. in a research note on Friday, June 17th. Guggenheim started coverage on Boston Scientific Corp. in a research note on Wednesday, June 8th. They set a “buy” rating and a $26.00 target price for the company. Zacks Investment Research raised Boston Scientific Corp. from a “hold” rating to a “buy” rating and set a $25.00 target price for the company in a research note on Thursday, May 12th. Needham & Company LLC increased their target price on Boston Scientific Corp. from $26.00 to $28.00 and gave the stock a “buy” rating in a research note on Friday, July 29th. Finally, Benchmark Co. increased their target price on Boston Scientific Corp. from $25.00 to $31.00 and gave the stock a “buy” rating in a research note on Thursday, July 28th. Six research analysts have rated the stock with a hold rating and twenty-one have assigned a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average target price of $25.03.
The company’s 50-day moving average is $23.98 and its 200-day moving average is $21.45. The company’s market cap is $33.11 billion.
Boston Scientific Corp. (NYSE:BSX) last posted its quarterly earnings results on Thursday, July 28th. The company reported $0.27 earnings per share (EPS) for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.27. During the same period in the prior year, the company posted $0.22 EPS. The company earned $2.13 billion during the quarter, compared to the consensus estimate of $2.05 billion. Boston Scientific Corp.’s quarterly revenue was up 15.4% on a year-over-year basis. On average, equities research analysts anticipate that Boston Scientific Corp. will post $1.10 EPS for the current fiscal year.
In other Boston Scientific Corp. news, SVP John Bradley Sorenson sold 2,500 shares of the company’s stock in a transaction on Thursday, August 11th. The stock was sold at an average price of $23.90, for a total value of $59,750.00. Following the transaction, the senior vice president now owns 12,615 shares of the company’s stock, valued at $301,498.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, SVP David A. Pierce sold 2,480 shares of the company’s stock in a transaction on Wednesday, July 20th. The shares were sold at an average price of $24.03, for a total value of $59,594.40. Following the completion of the transaction, the senior vice president now directly owns 28,080 shares in the company, valued at approximately $674,762.40. The disclosure for this sale can be found here.
A hedge fund recently raised its stake in Boston Scientific Corp. stock. Bank of Montreal Can increased its stake in shares of Boston Scientific Corp. (NYSE:BSX) by 18.1% during the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 522,744 shares of the company’s stock after buying an additional 80,052 shares during the period. Bank of Montreal Can’s holdings in Boston Scientific Corp. were worth $9,639,000 at the end of the most recent reporting period.
Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven core businesses: Interventional Cardiology, Peripheral Interventions (PI), Cardiac Rhythm Management (CRM), Electrophysiology (EP), Endoscopy, Urology and Pelvic Health, and Neuromodulation.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.